Merrion Pharmaceuticals Plc Announces Preliminary Results Outlining Successful Business and Financial Overview From 2010

Merrion Pharmaceuticals plc, (“Merrion” or the “Company”) (IEX: MERR) an international pharmaceutical product development company, announced today its preliminary financial results for the year ended 31 December 2010. Among the operating highlights is Merrion’s continuous work on four internal products based on its GIPET® technology; specifically its Orazol ™ oncology drug. The company has also

Read More...

Merrion Pharmaceuticals Plc Signs Feasibility and Option Agreement for 3 Drugs with International 'top ten' Pharmaceutical Company

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world’s top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion’s patented GIPET® technology to boost the bioavailablity of three of the ‘big pharma’ company’s compounds.

Read More...